Article info
Original research
Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments
- Correspondence to Professor Bruno Borghese, Service de Gynécologie Obstétrique 2 et Médecine de la Reproduction, Hôpital Cochin, Paris, France; bruno.borghese{at}aphp.fr
Citation
Identification of TP53 mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments
Publication history
- Received September 10, 2019
- Revision received January 31, 2020
- Accepted February 24, 2020
- First published March 12, 2020.
Article Versions
- You are currently viewing a Previous version of this article (4 May 2020).
- View the most recent version of this article
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.